Drug Innovation

Blog

Read about a last minute Biden administration plan the Trump administration should undo

CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs

For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation

PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls

PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027.  The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Biosimilars

The Biosimilar Promise

Despite Achievements, Barriers That Discourage Biosimilar Use Remain

Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden  | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Blog

Learn about case that could threaten medical innovation

PRI Files Amicus Brief in Key State Supreme Court Case That Could Upend Future Medical Innovation in California

In the case, the plaintiffs filed cases against the Gilead pharmaceutical company over the company’s failure to bring an alternative medication used to treat AIDS, hepatitis, and other diseases to the marketplace called TAF under a speedier timeline, even though TAF and the originally developed medicine called TDF are both ...
Biosimilars

The Biosimilar Promise

Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater

Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden  | October 28, 2024 READ PDF Executive Summary   Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Commentary

Learn more about how price fixing stifles innovation

New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation

Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Biosimilars

The Biosimilar Promise

Biosimilars Often Reduce Prices by 50 Percent or More

Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden  | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Blog

Learn how drug price controls hurt patients, innovation

Senator Sanders’ Price Controls Will Harm Patients

In a patently politicized press release, Senator Bernie Sanders (I-VT) who is  Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary

Read the latest on Biden administration's drug price controls

Drug Price Controls Underperform, Unworkable

According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
Commentary

Learn about the damage from lawsuit abuse

Tort Abuses Threat To Innovation And Product Availability

Not only is continued invention necessary for expanding our prosperity, but it is also key for mitigating problems such as global climate change or finding new technologies and treatments for troubling health conditions. Take the state and municipal lawsuits being filed against energy companies as an example. When announcing his ...
Blog

Read about a last minute Biden administration plan the Trump administration should undo

CMS’ Drug Price Controls Have Expanded to the Next 15 Medicare Part D Drugs

For every complex problem there is an answer that is clear, simple, and wrong. H.L. Mencken Back in 2022, the Biden Administration reasoned that drug costs are too high and devised a clear and simple answer: incorporate a Maximum Fair Price (MFP) provision into the Inflation Reduction Act of 2022 ...
Drug Innovation

PRI Responds to CMS Adding 15 Additional Drugs That Will Be Subjected to Government Price Controls

PRI’s scholars responded to today’s action by the Centers for Medicare & Medicaid (CMS) announcing 15 additional drugs under Medicare Part D that will be subject to government price setting effective January 1, 2027.  The action was authorized by the Inflation Reduction Act signed by President Biden in August 2022. ...
Biosimilars

The Biosimilar Promise

Despite Achievements, Barriers That Discourage Biosimilar Use Remain

Despite Achievements, Barriers That Discourage Biosimilar Use Remain By Wayne Winegarden  | December 2, 2024 READ PDF Executive Summary The Inflation Reduction Act’s price controls discourage biosimilar development. Payment system inefficiencies, such as the buy-and-bill payment system and rebate walls, disincentivize the use of lower cost biosimilars. Despite the savings ...
Blog

Learn about case that could threaten medical innovation

PRI Files Amicus Brief in Key State Supreme Court Case That Could Upend Future Medical Innovation in California

In the case, the plaintiffs filed cases against the Gilead pharmaceutical company over the company’s failure to bring an alternative medication used to treat AIDS, hepatitis, and other diseases to the marketplace called TAF under a speedier timeline, even though TAF and the originally developed medicine called TDF are both ...
Biosimilars

The Biosimilar Promise

Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater

Low-Cost Biosimilars Are Saving Billions, Potential Savings Are Even Greater By Wayne Winegarden  | October 28, 2024 READ PDF Executive Summary   Since 2019, biosimilars have obtained a majority share of most markets where they compete. The combination of lower prices (both biosimilar and originator) and rising market share could ...
Commentary

Learn more about how price fixing stifles innovation

New Schizophrenia Drug Represents Promise Of Pharmaceutical Innovation

Late last month, the U.S. Food and Drug Administration approved Bristol Myers Squibb’s KarXT, a treatment for schizophrenia. The drug, which will be marketed under the brand name Cobenfy, is promising not just because it is effective at treating the debilitating mental health condition. It also seems not to have the potentially harmful side ...
Biosimilars

The Biosimilar Promise

Biosimilars Often Reduce Prices by 50 Percent or More

Biosimilars Often Reduce Prices by 50 Percent or More By Wayne Winegarden  | October 1, 2024 READ PDF Executive Summary In the competitive biologic markets, biosimilars have reduced average prices by 56 percent. The lower prices have reduced total expenditures by 51 percent in the competitive biologic markets even though ...
Blog

Learn how drug price controls hurt patients, innovation

Senator Sanders’ Price Controls Will Harm Patients

In a patently politicized press release, Senator Bernie Sanders (I-VT) who is  Chairman of the Senate Health, Education, Labor, and Pensions (HELP) Committee, claims that the U.S. price of Ozempic is too high. As evidence, he cites generic companies that claim they can sell Ozempic for less than $100 a ...
Commentary

Read the latest on Biden administration's drug price controls

Drug Price Controls Underperform, Unworkable

According to the White House, the program will save the federal government an estimated $6 billion in 2026, the first year the new prices will be in effect, while reducing costs for seniors by $1.5 billion. Those figures might seem impressive. But they are almost certainly inflated. In fact, it’s ...
Commentary

Learn about the damage from lawsuit abuse

Tort Abuses Threat To Innovation And Product Availability

Not only is continued invention necessary for expanding our prosperity, but it is also key for mitigating problems such as global climate change or finding new technologies and treatments for troubling health conditions. Take the state and municipal lawsuits being filed against energy companies as an example. When announcing his ...
Scroll to Top